- Home
- BHAT vs PRLD Comparison
BHAT vs PRLD Comparison
Compare BHAT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHAT
- PRLD
- Stock Information
- Founded
- BHAT 2010
- PRLD 2016
- Country
- BHAT China
- PRLD United States
- Employees
- BHAT N/A
- PRLD N/A
- Industry
- BHAT Recreational Games/Products/Toys
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- BHAT Consumer Discretionary
- PRLD Health Care
- Exchange
- BHAT Nasdaq
- PRLD Nasdaq
- Market Cap
- BHAT 59.1M
- PRLD 69.1M
- IPO Year
- BHAT 2019
- PRLD 2020
- Fundamental
- Price
- BHAT $1.32
- PRLD $1.57
- Analyst Decision
- BHAT
- PRLD Strong Buy
- Analyst Count
- BHAT 0
- PRLD 3
- Target Price
- BHAT N/A
- PRLD $4.00
- AVG Volume (30 Days)
- BHAT 45.9K
- PRLD 3.7M
- Earning Date
- BHAT 12-22-2025
- PRLD 11-12-2025
- Dividend Yield
- BHAT N/A
- PRLD N/A
- EPS Growth
- BHAT N/A
- PRLD N/A
- EPS
- BHAT N/A
- PRLD N/A
- Revenue
- BHAT $18,724,190.00
- PRLD $10,500,000.00
- Revenue This Year
- BHAT N/A
- PRLD N/A
- Revenue Next Year
- BHAT N/A
- PRLD N/A
- P/E Ratio
- BHAT N/A
- PRLD N/A
- Revenue Growth
- BHAT N/A
- PRLD 250.00
- 52 Week Low
- BHAT $1.07
- PRLD $0.61
- 52 Week High
- BHAT $24.50
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- BHAT 40.80
- PRLD 50.29
- Support Level
- BHAT $1.07
- PRLD $1.50
- Resistance Level
- BHAT $1.57
- PRLD $1.69
- Average True Range (ATR)
- BHAT 0.08
- PRLD 0.18
- MACD
- BHAT -0.01
- PRLD -0.02
- Stochastic Oscillator
- BHAT 50.02
- PRLD 70.38
About BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.